Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ConvaTec ( (GB:CTEC) ) has shared an update.
ConvaTec Group PLC has executed a share buyback program, purchasing over 2 million of its ordinary shares through UBS AG London Branch. This buyback is part of a $300 million program announced in August 2025, aimed at optimizing the company’s capital structure and potentially enhancing shareholder value. The purchased shares will be held in treasury, and the current total voting rights stand at over 2 billion shares, excluding treasury shares.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Outperform.
ConvaTec’s overall stock score is driven primarily by its strong financial performance, which is offset by a cautious technical outlook and a relatively high valuation. The company’s robust financial health and effective cash flow management are significant strengths. However, the lack of positive technical indicators and a high P/E ratio suggest potential risks in the current market environment.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
ConvaTec Group PLC operates in the medical products and technologies industry, focusing on products and services for advanced wound care, ostomy care, continence and critical care, and infusion devices. The company aims to improve the lives of patients and healthcare professionals by providing innovative solutions in these areas.
Average Trading Volume: 7,932,098
Technical Sentiment Signal: Hold
Current Market Cap: £4.68B
For an in-depth examination of CTEC stock, go to TipRanks’ Overview page.